Now in its 2nd year, the World #OrphanDrug Congress 2011 returns to Geneva from 29th November 2011 to 1st December 2012 and offers an interactive forum enabling you to discover how the leading executives from the orphan drug industry are overcoming the challenges of orphan drug development and innovating against rare diseases.
The programme and speakers have been confirmed and this is your chance to download the brochure to find out more information!
Be part of the must attend orphan drug event of the year and take advantage of this fantastic opportunity to:
- Hear Hans Schikan, CEO, Prosensa; John Crowley, CEO, Amicus Therapeutics; David Aviezer, CEO, Protalix and David Meeker, COO, Genzyme debate best strategy to achieve the clinical added value require for orphan drug regulatory approval (page 5-6 of brochure).
- Lear from Jerry Zeldis, CEO, Celgene Global Health as he addresses the social and commercial benefits of investing into neglected diseases (page 4 of brochure).
- Hear Carlo Incerti, SVP Global Market Access, Genzyme deliver industry leading expertise on best practice for ensuring reimbursement and patient access (page 4 of brochure).
- Learn from and engage with pioneering patient organisations and rare disease patients themselves to understand their integral involvement in all aspects of orphan drug development.
REGISTER BEFORE 9th SEPTEMBER AND SAVE €660
To take advantage of our early-bird offer simply fax back the registration form on the back of the brochure to +44 (0) 207 242 2324 or register online